Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 183 participants.

Also called NCT01497522

  • Study
  • In this atlas

Overview

Design
Interventional study; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 183 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01497522
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01497522. Double masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01497522
Content hash
27b11cbea44f9989027d819ebedcb1c0ad2b0edaae462f556d62d4133152fdb0